Synchrony to Announce Fourth Quarter 2021 Financial Results on January 28, 2022
Get Alerts SYF Hot Sheet
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.6%
Revenue Growth %: -100.0%
Join SI Premium – FREE
STAMFORD, Conn., Jan. 4, 2022 /PRNewswire/ -- Synchrony (NYSE: SYF) plans to report its fourth quarter 2021 results on Friday, January 28, 2022. The earnings release and presentation materials are scheduled to be released and posted to the Investor Relations section of the Company's website, www.investors.synchronyfinancial.com, at approximately 6:00 a.m. Eastern Time. A conference call to discuss Synchrony's results will be held at 8:00 a.m. Eastern Time on that day; the live audio webcast and replay can be accessed through the same website under Events and Presentations.
About Synchrony
Synchrony (NYSE: SYF) is a premier consumer financial services company. We deliver a wide range of specialized financing programs, as well as innovative consumer banking products, across key industries including digital, retail, home, auto, travel, health and pet. Synchrony enables our partners to grow sales and loyalty with consumers. We are one of the largest issuers of private label credit cards in the United States; we also offer co-branded products, installment loans and consumer financing products for small- and medium-sized businesses, as well as healthcare providers.
Synchrony is changing what's possible through our digital capabilities, deep industry expertise, actionable data insights, frictionless customer experience and customized financing solutions.
For more information, visit www.synchrony.com and Twitter: @Synchrony.
Contacts
Investor Relations:Kathryn Miller(203) 585-6291[email protected]
Public Relations: Lisa Lanspery(203) 585-6143[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/synchrony-to-announce-fourth-quarter-2021-financial-results-on-january-28-2022-301453848.html
SOURCE Synchrony
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LG Energy Solution Makes Progress Amid Market Uncertainties, Aims to Strengthen Fundamental Competitiveness This Year
- ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST
- Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Twitter, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!